Claims for Patent: 10,292,937

Summary for Patent: 10,292,937

Title:	Methods of treatment of attention deficit hyperactivity disorder
Abstract:	Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.
Inventor(s):	Lickrish; David (Grand Cayman, KY), Zhang; Feng (Pflugerville, TX)
Assignee:	IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC. (Camana Bay, KY)
Application Number:	15/470,697
Patent Claims:	1. A method of treating a subject with a disorder or condition responsive to the administration of a methylphenidate, comprising: orally administering an effective amount of a methylphenidate or a pharmaceutical salt thereof in a formulation comprising one or more water soluble capsules containing a unit dose of methylphenidate or a pharmaceutical salt thereof in a solid dosage form that comprises a plurality of beads, wherein said beads comprise a sustained release formulation comprising the methylphenidate or a pharmaceutical salt thereof enclosed in a delayed release coating that is insoluble in an aqueous medium at pH below 5.5, wherein the sustained release formulation comprises a drug-containing core enclosed in a sustained release coating comprising ethyl cellulose and hydroxypropyl cellulose in a ratio of about 1:3 to 1:5, dibutyl sebacate and from 25% to 50% magnesium stearate, and wherein the method comprises administering the unit dose form 5-8 hours prior to the desired treatment period. 2. The method of claim 1, wherein the delayed release coating comprises methacrylic acid copolymer type-B, mono- and di-glycerides and polysorbate 80. 3. The method of claim 1, wherein administration of the formulation is timed to administer the drug prior to a subject's bed time and to allow the subject to sleep during a period of absorption of less than 5% of the total therapeutic dose and to have absorbed a therapeutic level of drug at the anticipated time of awakening. 4. The method of claim 1, wherein the formulation is administered at night. 5. The method of claim 1, wherein the formulation is administered once a day. 6. The method of claim 1, wherein the formulation is administered more than once a day. 7. The method of claim 1, wherein the formulation is administered to a patient in a fasted state. 8. The method of claim 1, wherein the disorder or condition is attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms in schizophrenia, chronic fatigue, fatigue associated with chemotherapy or binge eating disorder. 9. The method of claim 1, wherein the disorder or condition is attention deficit disorder or attention deficit hyperactivity disorder. 10. The method of claim 1, wherein the disorder is binge eating disorder.